Home › Companies › ACADIA PHARMACEUTICALS INC. › 2024-2025

ACADIA PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and ACADIA PHARMACEUTICALS INC.’s Form 8-K, filed May 29, 2025 (Item 5.07 on EDGAR). Page generated October 18, 2026.

5Ballot items
345Asset managers
1,971Fund votes
May 29, 2025Meeting date

Results at a glance

Meeting of May 29, 2025: 5 items on ACADIA PHARMACEUTICALS INC.’s Form 8-K, filed May 29, 2025: 2 approved · 3 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ACADIA PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ACADIA PHARMACEUTICALS INC.

These tallies are ACADIA PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 29, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ACADIA PHARMACEUTICALS INC. — official shareholder meeting results, meeting held May 29, 2025
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Catherine Owen Adams	142,149,434	--	--	2,923,385	10,343,307	98%	Not verified	—
Elect Director: Laura A. Brege	129,105,717	--	--	15,967,102	10,343,307	89%	Not verified	—
Elect Director: Elizabeth A. Garofalo, M.D.	140,048,500	--	--	5,024,319	10,343,307	97%	Not verified	—
the approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the Company's definitive proxy statement for the 2025 Annual Meeting filed with the Securities and Exchange Commission on April 25, 2025, which w	142,156,754	2,807,251	108,814	--	10,343,307	98%	Approved	—
the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, which was ratified by the following vote	154,454,616	926,490	35,019	--	--	99.4%	Approved	—

Source: ACADIA PHARMACEUTICALS INC., Form 8-K, filed with the SEC on May 29, 2025 — read the filing on EDGAR.

How asset managers voted at the ACADIA PHARMACEUTICALS INC. 2024-2025 meeting

Each item below shows how the 345 asset managers that disclosed a ACADIA PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Catherine Owen Adams

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 142,149,434WITHHELD: 2,923,385

Details: description as filed, official tally, votes by 95 asset managers

Description as filed by funds: To elect three Class III directors to hold office until the Company's 2028 Annual Meeting of Stockholders: Catherine Owen Adams

ACADIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Catherine Owen Adams”): 142,149,434 for, 2,923,385 withheld, per its Form 8-K filed May 29, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 95 asset managers below reported 48,840,700 for, 529,824 withheld, 69,684 abstained.

FOR

FOR: 48,840,700ABSTAIN: 69,684WITHHOLD: 529,824

Largest asset managers voting on “To elect three Class III directors to hold office until the Company's 2028 Annual Meeting of Stockholders: Cat” at ACADIA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Withheld	Vote
Vanguard	15,248,011	2	0	For
BlackRock	10,085,110	0	0	For
State Street	4,190,066	0	0	For
Fidelity	3,051,362	0	0	For
First Trust	2,492,130	0	0	For
American Century	1,747,917	0	0	For
Charles Schwab	1,083,011	0	0	For
TIAA	1,080,741	0	0	For
John Hancock	916,097	0	0	For
Dimensional	879,829	0	0	For
MUTUAL FUND SERIES TRUST	852,845	0	0	For
ALGER FUNDS	796,648	0	0	For
Columbia Threadneedle	613,824	0	0	For
T. Rowe Price	415,304	0	0	For
Janus Detroit Street Trust	364,367	0	0	For
Equitable	333,495	0	0	For
Goldman Sachs	317,126	0	0	For
World Funds Trust	300,000	0	0	For
Erste Asset Management GmbH	0	0	242,300	Withhold
Principal	119,845	0	117,890	Mixed
LIBERTY ALL STAR GROWTH FUND INC.	232,695	0	0	For
Jackson National	231,693	0	0	For
QUANTITATIVE MASTER SERIES LLC	206,561	0	0	For
Exchange Place Advisors Trust	188,100	0	0	For
Prudential/PGIM	179,147	0	0	For

Showing the 25 largest of 95 asset managers. See all 95 in the interactive database.

2. Elect Director: Elizabeth A. Garofalo, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 140,048,500WITHHELD: 5,024,319

Details: description as filed, official tally, votes by 95 asset managers

Description as filed by funds: To elect three Class III directors to hold office until the Company's 2028 Annual Meeting of Stockholders: Elizabeth A. Garofalo, M.D.

ACADIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Elizabeth A. Garofalo, M.D.”): 140,048,500 for, 5,024,319 withheld, per its Form 8-K filed May 29, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 95 asset managers below reported 47,759,049 for, 1,611,472 withheld, 69,687 abstained.

FOR

FOR: 47,759,049ABSTAIN: 69,687WITHHOLD: 1,611,472

Largest asset managers voting on “To elect three Class III directors to hold office until the Company's 2028 Annual Meeting of Stockholders: Eli” at ACADIA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Withheld	Vote
Vanguard	15,248,008	5	0	For
BlackRock	10,085,110	0	0	For
State Street	4,190,066	0	0	For
Fidelity	3,051,362	0	0	For
First Trust	2,492,130	0	0	For
American Century	1,747,917	0	0	For
Charles Schwab	1,083,011	0	0	For
TIAA	1,080,741	0	0	For
John Hancock	916,097	0	0	For
Dimensional	879,829	0	0	For
MUTUAL FUND SERIES TRUST	852,845	0	0	For
ALGER FUNDS	796,648	0	0	For
Columbia Threadneedle	613,824	0	0	For
T. Rowe Price	0	0	415,304	Withhold
Janus Detroit Street Trust	364,367	0	0	For
Equitable	191,115	0	142,380	Mixed
Goldman Sachs	317,126	0	0	For
World Funds Trust	300,000	0	0	For
Erste Asset Management GmbH	0	0	242,300	Withhold
Principal	119,845	0	117,890	Mixed
LIBERTY ALL STAR GROWTH FUND INC.	232,695	0	0	For
Jackson National	14,382	0	217,311	Mixed
QUANTITATIVE MASTER SERIES LLC	206,561	0	0	For
Exchange Place Advisors Trust	188,100	0	0	For
Prudential/PGIM	179,147	0	0	For

Showing the 25 largest of 95 asset managers. See all 95 in the interactive database.

3. Elect Director: Laura A. Brege

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%

FOR: 129,105,717WITHHELD: 15,967,102

Details: description as filed, official tally, votes by 95 asset managers

Description as filed by funds: To elect three Class III directors to hold office until the Company's 2028 Annual Meeting of Stockholders: Laura A. Brege

ACADIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Laura A. Brege”): 129,105,717 for, 15,967,102 withheld, per its Form 8-K filed May 29, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 95 asset managers below reported 41,526,838 for, 7,843,670 withheld, 69,699 abstained.

FORWITHHOLD

FOR: 41,526,838ABSTAIN: 69,699WITHHOLD: 7,843,670

Largest asset managers voting on “To elect three Class III directors to hold office until the Company's 2028 Annual Meeting of Stockholders: Lau” at ACADIA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Withheld	Vote
Vanguard	15,247,996	17	0	For
BlackRock	10,085,110	0	0	For
State Street	16,768	0	4,173,298	Withhold
Fidelity	3,051,362	0	0	For
First Trust	2,492,130	0	0	For
American Century	1,747,917	0	0	For
Charles Schwab	1,083,011	0	0	For
TIAA	0	0	1,080,741	Withhold
John Hancock	821,803	0	94,294	Mixed
Dimensional	0	0	879,829	Withhold
MUTUAL FUND SERIES TRUST	852,845	0	0	For
ALGER FUNDS	796,648	0	0	For
Columbia Threadneedle	613,824	0	0	For
T. Rowe Price	0	0	415,304	Withhold
Janus Detroit Street Trust	364,367	0	0	For
Equitable	191,115	0	142,380	Mixed
Goldman Sachs	317,126	0	0	For
World Funds Trust	300,000	0	0	For
Erste Asset Management GmbH	242,300	0	0	For
Principal	119,592	0	118,143	Mixed
LIBERTY ALL STAR GROWTH FUND INC.	232,695	0	0	For
Jackson National	0	0	231,693	Withhold
QUANTITATIVE MASTER SERIES LLC	206,561	0	0	For
Exchange Place Advisors Trust	188,100	0	0	For
Prudential/PGIM	165,950	0	13,197	Mixed

Showing the 25 largest of 95 asset managers. See all 95 in the interactive database.

4. the approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the…

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 15 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%

FOR: 142,156,754AGAINST: 2,807,251

Details: description as filed, official tally, votes by 345 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.

ACADIA PHARMACEUTICALS INC.’s own tally for this item (“the approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the Company's definitive proxy statement for the 2025 Annual Meeting filed with the Securities and Exchan”): 142,156,754 for, 2,807,251 against — passed, per its Form 8-K filed May 29, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “In addition to the election of three Class III directors, the following matters were submitted to a vote of the stockholders at the 2025 Annual Meeting: (i) the approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the Company's definitive pr…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 93 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at ACADIA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	15,230,828	17,185	For
BlackRock	10,085,110	0	For
State Street	4,184,297	5,769	For
Fidelity	3,051,362	0	For
First Trust	2,492,130	0	For
American Century	1,747,917	0	For
Charles Schwab	1,083,011	0	For
TIAA	1,080,741	0	For
John Hancock	916,097	0	For
Dimensional	879,829	0	For
MUTUAL FUND SERIES TRUST	852,845	0	For
ALGER FUNDS	796,648	0	For
Columbia Threadneedle	613,824	0	For
T. Rowe Price	415,304	0	For
Janus Detroit Street Trust	364,367	0	For
Equitable	333,495	0	For
Goldman Sachs	317,126	0	For
World Funds Trust	300,000	0	For
Principal	237,735	0	For
LIBERTY ALL STAR GROWTH FUND INC.	232,695	0	For
Jackson National	231,693	0	For
QUANTITATIVE MASTER SERIES LLC	206,561	0	For
Exchange Place Advisors Trust	188,100	0	For
Prudential/PGIM	179,147	0	For
Lincoln Financial	173,769	0	For

Fund voting reports, all 93 managers: 49,158,906 for, 45,492 against, 16,667 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 273 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at ACADIA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
BAKER BROS. ADVISORS LP	43,083,688	0	For
RTW INVESTMENTS, LP	6,824,479	0	For
State Street	6,572,557	7,469	For
Point72	5,430,913	0	For
BlackRock	4,322,600	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,974,976	0	For
American Century	1,903,018	0	For
DE Shaw	1,848,380	0	For
WEATHERBIE CAPITAL, LLC	1,692,467	0	For
Two Sigma	1,185,683	0	For
Northern Trust	1,123,776	0	For
Charles Schwab	1,111,406	0	For
Nuveen	1,092,489	0	For
ROCKEFELLER FINANCIAL LLC	876,348	0	For
JACOBS LEVY EQUITY MANAGEMENT, INC	839,770	0	For
John Hancock	779,944	0	For
MELLON INVESTMENTS Corp	777,981	0	For
PRINCIPAL GLOBAL INVESTORS	761,595	0	For
JUPITER ASSET MANAGEMENT LTD	711,003	0	For
STRS OHIO	694,341	0	For
Goldman Sachs	645,878	0	For
T. Rowe Price	607,010	0	For
Renaissance	511,140	0	For
Frazier Life Sciences Management, L.P.	470,338	0	For
RICE HALL JAMES & ASSOCIATES, LLC	467,909	0	For

Institutional-manager reports, all 273 managers: 99,186,748 for, 1,320,685 against, 242,300 withheld, 6,522 not voted. Showing the 25 largest; see all in the interactive database.

5. the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.4% Approved · of votes cast

FOR 99.4%

FOR: 154,454,616AGAINST: 926,490

Details: description as filed, official tally, votes by 95 asset managers

Description as filed by funds: To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.

ACADIA PHARMACEUTICALS INC.’s own tally for this item (“the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, which was ratified by the following vote”): 154,454,616 for, 926,490 against — passed, per its Form 8-K filed May 29, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(ii) the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, which was ratified by the following vote:”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 95 asset managers below reported 49,417,410 for, 2,442 against, 16,667 abstained.

FOR

FOR: 49,417,410AGAINST: 2,442ABSTAIN: 16,667

Largest asset managers voting on “To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm fo” at ACADIA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	15,248,012	1	For
BlackRock	10,085,110	0	For
State Street	4,189,808	258	For
Fidelity	3,051,362	0	For
First Trust	2,492,130	0	For
American Century	1,747,917	0	For
Charles Schwab	1,083,011	0	For
TIAA	1,080,741	0	For
John Hancock	916,097	0	For
Dimensional	879,829	0	For
MUTUAL FUND SERIES TRUST	852,845	0	For
ALGER FUNDS	796,648	0	For
Columbia Threadneedle	613,824	0	For
T. Rowe Price	415,304	0	For
Janus Detroit Street Trust	364,367	0	For
Equitable	333,495	0	For
Goldman Sachs	317,126	0	For
World Funds Trust	300,000	0	For
Erste Asset Management GmbH	242,300	0	For
Principal	237,735	0	For
LIBERTY ALL STAR GROWTH FUND INC.	232,695	0	For
Jackson National	231,693	0	For
QUANTITATIVE MASTER SERIES LLC	206,561	0	For
Exchange Place Advisors Trust	188,100	0	For
Prudential/PGIM	179,147	0	For

Showing the 25 largest of 95 asset managers. See all 95 in the interactive database.

Largest ACADIA PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 167,116,045 shares outstanding at the time of that meeting.

Fund voting reports: top ACADIA PHARMACEUTICALS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2024-2025
#	Asset manager	% of shares outstanding
1	Vanguard	9.12%
2	BlackRock	6.03%
3	State Street	2.51%
4	Fidelity	1.83%
5	First Trust	1.49%
6	American Century	1.05%
7	Charles Schwab	0.65%
8	TIAA	0.65%
9	John Hancock	0.55%
10	Dimensional	0.53%

Institutional-manager reports: top ACADIA PHARMACEUTICALS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2024-2025
#	Asset manager	% of shares outstanding
1	BAKER BROS. ADVISORS LP	25.78%
2	RTW INVESTMENTS, LP	4.08%
3	State Street	3.94%
4	Point72	3.25%
5	BlackRock	2.59%
6	GEODE CAPITAL MANAGEMENT, LLC	1.78%
7	American Century	1.14%
8	DE Shaw	1.11%
9	WEATHERBIE CAPITAL, LLC	1.01%
10	Two Sigma	0.71%

Reported ACADIA PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

ACADIA PHARMACEUTICALS INC. holdings and ownership disclosed for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Baker Bros. Advisors LP	25.93%	DEF14A
Julian C. Baker	25.93%	DEF14A
Stephen R. Biggar	25.87%	DEF14A
BlackRock	12.79%	13F
Vanguard Group	9.10%	13F
RTW Investments, LP	4.28%	13G
State Street	4.18%	13F
Morgan Stanley	2.80%	13F
Point72	2.78%	13F
Geode Capital	1.77%	13F

Percentages above are of 167,116,045 shares outstanding, as reported by ACADIA PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ACADIA PHARMACEUTICALS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At ACADIA PHARMACEUTICALS INC.'s shareholder meeting held May 29, 2025, in the 2024-2025 proxy season, 345 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,971 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — ACADIA PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ACADIA PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 29, 2025.

ACADIA PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.